Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EARLY CAPTOPRIL TREATMENT REDUCES PLASMA ENDOTHELIN CONCENTRATIONS INTHE ACUTE AND SUBACUTE PHASES OF MYOCARDIAL-INFARCTION - A PILOT-STUDY
Autore:
DIPASQUALE P; VALDES L; ALBANO V; BUCCA V; SCALZO S; PIERI D; MARINGHINI G; PATERNA S;
Indirizzi:
VIA VAL PLATANI 3 I-90144 PALERMO ITALY UNIV PALERMO,INST PHARMACOL PALERMO ITALY UNIV PALERMO,INST INTERNAL MED PALERMO ITALY CASA DEL SOLE HOSP,SERV HEMODYNAM PALERMO ITALY
Titolo Testata:
Journal of cardiovascular pharmacology
fascicolo: 2, volume: 29, anno: 1997,
pagine: 202 - 208
SICI:
0160-2446(1997)29:2<202:ECTRPE>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC HEART-FAILURE; NITRIC-OXIDE RELEASE; RELAXING FACTOR; HUMAN ARTERIES; L-ARGININE; THROMBOLYSIS; MORTALITY; BRADYKININ; CELLS; REPERFUSION;
Keywords:
CAPTOPRIL; ENDOTHELIN; INFARCTION; THROMBOLYSIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
52
Recensione:
Indirizzi per estratti:
Citazione:
P. Dipasquale et al., "EARLY CAPTOPRIL TREATMENT REDUCES PLASMA ENDOTHELIN CONCENTRATIONS INTHE ACUTE AND SUBACUTE PHASES OF MYOCARDIAL-INFARCTION - A PILOT-STUDY", Journal of cardiovascular pharmacology, 29(2), 1997, pp. 202-208

Abstract

It has been reported that endothelin-l (ET-1) increases in acute myocardial infarction (AMI). Experimental studies showed that captopril administration reduces ET-1 secretion. In addition, it was reported thatthe increased ET-1 levels are a negative prognostic index. The study sought to verify whether captopril can reduce plasma ET levels in the acute and subacute phases of reperfused anterior AMI. Forty-five patients, hospitalized for suspected anterior AMI within 4 h from the onsetof symptoms, suitable for thrombolysis (first episode), Killip class 1-2, were randomized (double blind) into two groups: group A (23; seven women/16 men) received captopril (as first dose) 2-4 h after starting thrombolysis (the dose was then increased up to 25 mg every 8 h). Group B (22; five women/17 men) received placebo after thrombolysis. Allthe patients met the reperfusion criteria. The two groups were similar with regard to age, sex, CK peak, ejection fraction, end-systolic volume and risk factors. Plasma ET levels were measured at entry, and 2,12, 24, 48, and 72 h after starting thrombolysis. Mean concentrationsof ET +/- SD: Group A basal, 1.50 +/- 0.67; at 2 h, 2.31; +/- 1.24; 12 h, 1.84 +/- 1.45; 24 h, 1.30 +/- 0.72; 48 h, 0.95 +/- 0.50; 72 h, 0.60 +/- 0.15 fmol/ml; p < 0.001. Group B basal, 1.58 +/- 0.83; at 2 h, 2.38 +/- 1.35; 12 h, 2.33 +/- 1.71; 24 h, 1.80 +/- 1.41; 48 h, 1.46 +/- 0.88; 72 h, 0.93 +/- 0.44 fmol/ml; p < 0.001. Difference between thetwo groups was significant at the beginning of the test (between 2 and 12 h, p\=\10.002). After that, the values of the plasma endothelin decreased in parallel, p < 0.001. Our data suggest that captopril affects plasma ET levels in the acute and subacute phases of AMI. Moreover,these results provide additional evidence for a beneficial effect of early captopril treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 03:13:21